U.S. markets closed

MedAvail Holdings, Inc (MDVL)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
13.89-0.53 (-3.68%)
At close: 4:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close14.42
Open14.30
Bid13.51 x 800
Ask16.98 x 1000
Day's Range13.56 - 14.30
52 Week Range8.89 - 46.20
Volume38,291
Avg. Volume107,224
Market Cap439.881M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • MYOS CORP Secures Fourth Patent as Part of R&D Drive to Address Healthcare Burden of Sarcopenia and Muscle-Related Disorders
    PR Newswire

    MYOS CORP Secures Fourth Patent as Part of R&D Drive to Address Healthcare Burden of Sarcopenia and Muscle-Related Disorders

    MYOS CORP ("MYOS" or the "Company"), a research-based advanced nutrition company with divisions that address both Human Nutrition and Animal Health, announced today that it has been granted United States Patent #10,925,904 by the United States Patent and Trademark Office (USPTO). The new patent, titled "Methods and Compositions for Improving Skeletal Muscle Protein Fractional Synthetic Rate," protects advanced technologies related to improving skeletal muscle protein synthetic rate in older mammals through the administration of proprietary nutritional compositions such as MYOS' advanced nutrition product, Fortetropin®.

  • MedAvail to Present at the Cowen 41st Annual Health Care Conference
    Business Wire

    MedAvail to Present at the Cowen 41st Annual Health Care Conference

    MedAvail Holdings, Inc. (Nasdaq: MDVL) ("MedAvail") a technology-enabled retail pharmacy company, today announced that the company will be participating in the upcoming Cowen 41st Annual Health Care Conference.

  • MedAvail Announces Preliminary Fourth Quarter and Full Year 2020 Results
    Business Wire

    MedAvail Announces Preliminary Fourth Quarter and Full Year 2020 Results

    MedAvail Holdings, Inc. (Nasdaq: MDVL) ("MedAvail") a technology-enabled pharmacy company, today announced preliminary financial and operational results for the fourth quarter and full year 2020.